Several drugs with inhibitory VEGFR-2 activity have been recognized and clinically approved as anticancer drugs.12,13,16 Anti-angiogenic active agents reduce the vascular permeability and enhance the extravasation of the therapeutic small molecules.17 However, some adverse effects have been reported to be associated with anti-VEGFR therapeutics including dermatologic disorders (skin rash, depigmentation and mucositis), painful hand-foot skin reactions and pruritus.18 The gene discussed is KDR; the disease is mucositis.